Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2013 Feb;93(2):170-6. doi: 10.1038/clpt.2012.220. Epub 2012 Nov 7.

Economic and technological drivers of generic sterile injectable drug shortages.

Author information

  • 1Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Erratum in

  • Clin Pharmacol Ther. 2013 Apr;93(4):366.
  • Clin Pharmacol Ther. 2013 May;93(5):451.

Abstract

Over the past few years, an increasing number of critically needed medicines have been in short supply. Using economic theory to frame the drug-shortage problem, this paper explores why and how manufacturing-quality problems could combine with other economic and technological factors to result in shortages of generic sterile injectable drugs. The fundamental problem we identify is the inability of the market to observe and reward quality. This lack of reward for quality can reinforce price competition and encourage manufacturers to keep costs down by minimizing quality investments. The US Food and Drug Administration's (FDA's) need to use its regulatory flexibility, on behalf of patients, to avoid shortages of medically necessary drugs may further strengthen the incentive to "push the envelope" on quality. These dynamics may have produced a market situation in which quality problems have become sufficiently common and severe to result in drug shortages.

PMID:
23337525
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk